Osteoporosis Associated with Illnesses and Medications

Osteoporosis, Two-Volume Set

Volumn , Issue , 2008, Pages 1283-1314

  Lowe, Hyesoo ^a   Shane, Elizabeth ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959473537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370544-0.50054-9     Document Type: Chapter

References (356)

1. Thrailkill K.M., Lumpkin C.K., Bunn R.C., Kemp S.F., Fowlkes J.L. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005, 289:E735-E745.
2. Levin M.E., Boisseau V.C., Avioli L.V. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 1976, 294:241-245.
3. Rosenbloom A.L., Lezotte D.C., Weber F.T., Gudat J., Heller D.R., Weber M.L., Klein S., Kennedy B.B. Diminution of bone mass in childhood diabetes. Diabetes 1977, 26:1052-1055.
4. Santiago J.V., McAlister W.H., Ratzan S.K., Bussman Y., Haymond M.V., Shakelford G., Weldon V.V. Decreased cortical thickness and osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab 1977, 45:845-848.
5. Thoger C., Ibsen K.K., Christiansen J.S., et al. Diabetes mellitus, skeletal age and bone mineral content in children. Acta Endocrinol Suppl 1978, 58:219.
6. McNair P., Madsbad S., Christiansen C., Faber O.K., Binder G. Osteopenia in insulin-treated diabetes mellitus. Its relation to age at onset, sex and duration of disease. Diabetologia 1978, 15:87-90.
7. Shore R.M., Chesney R.W., Mazess R.B., Rose P.G., Bargman G.J. Osteopenia in juvenile diabetes. Calcif Tissue Int 1981, 33:455-457.
8. Frazer T.E., White N.H., Hough S., Santiago J.V., McGee B.R., Bryce G., Mallon J., Avioli L.V. Alterations in circulating vitamin D metabolites in the young insulin-dependent diabetic. J Clin Endocrinol Metab 1981, 53:1154-1159.
9. Wiske P.S., Wentworth S.M., Norton J.A., Epstein S., Johnston C.C. Evaluation of bone mass and growth in young diabetics. Metabolism 1982, 31:848-854.
10. Hui S.L., Epstein S., Johnston C.C. A prospective study of bone mass in patients with type 1 diabetes. J Clin Endocrinol Metab 1985, 60:74-80.
11. Hough F.S. Alterations of bone and mineral metabolism in diabetes mellitus. Part II. South Afr Med 1987, 72:120-126.
12. Leon M., Larrodera L., Lledo G., Hawkins F. Study of bone loss in diabetes mellitus type 1. Diabetes Res Clin Pract 1989, 6:237-242.
13. Saggese G., Bertelloni S., Baroncelli G.I., Federico G., Calisti L., Fusaro C. Bone demineralization and impaired mineral metabolism in insulin-dependent diabetes mellitus. Helv Paediatr Acta 1988, 43:405-414.
14. Weber G., Beccaria L., de'Angelis M., Mora S., Galli L., Cazzuffi M.A., Turba F., Frisone F., Guarneri M.P., Chiumello G. Bone mass in young patients with type 1 diabetes. Bone Miner 1990, 8:23-30.
15. Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991, 49:155-160.
16. Auverx J., Dequeker J., Bouillon R., Geusens P., Nijs J. Mineral metabolism and bone mass at peripheral and axial skeleton in diabetes mellitus. Diabetes 1988, 37:8-12.
17. Forst T., Pfutzner A., Kann P., Schehler B., Lobmann R., Schafer H., Andreas J., Bockisch A., Beyer J. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995, 12:874-879.
18. Kayath M.J., Dib S.A., Vieira J.G. Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabetes Complications 1994, 8:97-104.
19. Kemink S.A., Hermus A.R., Swinkels L.M., Lutterman J.A., Smals A.G. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 2000, 23:295-303.
20. Munoz-Torres M., Jodar E., Escobar-Jimenez F., Lopez-Ibarra P.J., Luna J.D. Bone mineral density measured by dual x-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int 1996, 58:316-319.
21. Roe T.F., Mora S., Costin G., Kaufman F., Carlson M.E., Gilsanz V. Vertebral bone density in insulin-dependent diabetic children. Metabolism 1991, 40:967-971.
22. Lopez-Ibarra P.J., Pastor M.M., Escobar-Jimenez F., Pardo M.D., Gonzalez A.G., Luna J.D., Requena M.E., Diosdado M.A. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 2001, 7:346-351.
23. De Schepper J., Smitz J., Rosseneu S., Bollen P., Louis O. Lumbar spine bone mineral density in diabetic children with recent onset. Horm Res 1998, 50:193-196.
24. Mathiassen B., Nielsen S., Ditzel J., Rodbro P. Long-term bone loss in insulin-dependent diabetes mellitus. J Int Med 1990, 227:325-327.
25. Weinstock R.S., Goland R.S., Shane E., Clemens T.L., Lindsay R., Bilezikian J.P. Bone mineral density in women with type II diabetes mellitus. J Bone Miner Res 1989, 4:97-101.
26. Meema H.E., Meema S. The relationship of diabetes mellitus and body weight to osteoporosis in elderly females. J Can Med Assoc 1967, 96:132-139.
27. Ishida H., Seino Y., Matsukura S., Ikeda M., Yawata M., Yamashita G., Ishizuka S., Imura H. Diabetic osteopenia and circulating levels of vitamin D metabolites in type 2 (non insulin-dependent) diabetes. Metabolism 1985, 34:797-801.
28. Isaia G., Bodrato L., Carlevatto V., Mussetta M., Salamano G., Molinatti G.M. Osteoporosis in type II diabetes. Acta Diabetol 1987, 24:305-310.
29. Johnston C.C., Hui S.L., Longcope C. Bone mass and sex steroid concentrations in postmenopausal Caucasian diabetics. Metabolism 1985, 34:544-550.
30. Gregorio F., Cristallini S., Santeusanio F., Fillipponi P., Fumelli P. Osteopenia associated with non-insulin-dependent diabetes mellitus: What are the causes?. Diabetes Res Clin Pract 1994, 23:43-54.
31. Seino Y., Ishida H., Himura H. Diabetic osteopenia in central Japan. Diabetes Metab 1985, 11:216-219.
32. Buysschaert M., Cauwe F., Jamart J., Brichant C., DeCoster P., Magnan A., Donckier J. Proximal femur density in type 1 and 2 diabetic patients. Diabetes Metab 1992, 18:32-37.
33. Montecucco C., Baldi F., Caporali R., et al. Serum osteocalcin (bone Gla-protein) and bone mineral content in non-insulin dependent diabetes. Diabetes Nutr Metab 1990, 4:311-316.
34. Barrett-Connor E., Holbrooke T.L. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 1992, 268:3333-3337.
35. Giacca A., Fassina A., Caviezel F., Cattaneo A.G., Caldirola G., Pozza G. Bone mineral density in diabetes mellitus. Bone 1988, 9:29-36.
36. Wakasugy M., Wakao R., Tawata M., Gan N., Koizumi K., Onaya T. Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin dependent diabetes mellitus. Bone 1993, 14:29-33.
37. Bonds D.E., Larson J.C., Schwartz A.V., Strotmeyer E.S., Robbins J., Rodriguez B.L., Johnson K.C., Margolis K.L. Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006, 91:3404-3410.
38. Dennison E.M., Syddall H.E., Aihie Sayer A., Craighead S., Phillips D.I., Cooper C. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: Evidence for an indirect effect of insulin resistance?. Diabetologia 2004, 47:1963-1968.
39. Kao W.H., Kammerer C.M., Schneider J.L., Bauer R.L., Mitchell B.D. Type 2 diabetes is associated with increased bone mineral density in Mexican-American women. Arch Med Res 2003, 34:399-406.
40. Strotmeyer E.S., Cauley J.A., Schwartz A.V., Nevitt M.C., Resnick H.E., Zmuda J.M., Bauer D.C., Tylavsky F.A., de Rekeneire N., Harris T.B., Newman A.B. Diabetes is associated independently of body composition with BMD and bone volume in older White and Black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004, 19:1084-1091.
41. Hanley D.A., Brown J.P., Tenenhouse A., Olszynski W.P., Ioannidis G., Berger C., Prior J.C., Pickard L., Murray T.M., Anastassiades T., Kirkland S., Joyce C., Joseph L., Papaioannou A., Jackson S.A., Poliquin S., Adachi J.D. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: Cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 2003, 18:784-790.
42. Lunt M., Masaryk P., Scheidt-Nave C., Nijs J., Poor G., Pols H., Falch J.A., Hammermeister G., Reid D.M., Benevolenskaya L., Weber K., Cannata J., O'Neill T.W., Felsenberg D., Silman A.J., Reeve J. The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: The EVOS study. Osteoporos Int 2001, 12:688-698.
43. Tuominen J.T., Impivaara O., Puukka P., Ronnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999, 22:1196-1200.
44. Majima T., Komatsu Y., Yamada T., Koike Y., Shigemoto M., Takagi C., Hatanaka I., Nakao K. Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients. Osteoporos Int 2005, 16:907-913.
45. Seeley D.G., Kelsey J., Jergas M., Nevitt M.C. Predictors of ankle and foot fractures in older women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996, 11:1347-1355.
46. Alffram P.A. An epidemiologic study of cervical and trochanteric fractures of the femur in an urban population. Acta Orthop Scand Suppl 1964, 65:75-77.
47. Menczel J., Makin M., Robin G. Prevalence of diabetes mellitus in Jerusalem; Its association with osteoporosis. Isr J Med Sci 1972, 918-919.
48. Hutchinson T.A., Polansky S.M., Feinstein A.R. Postmenopausal oestrogens protect against fractures of hip and radius; A case-control study. Lancet 1979, 705-708.
49. Gallagher J.C., Melton L.J., Riggs B.L. Examination of prevalence rates of possible risk factors in population with a fracture of the proximal femur. Clin Orthop 1980, 153:158-165.
50. Weintroub S., Eisenberg D., Tardiman R., Weissman S.L., Salama R. Is diabetic osteoporosis due to microangiopathy?. Lancet 1980, 2.
51. Paganini-Hill A.L., Ross R.K., Gerkins V.R., Henderson B.E., Arthur M., Mack T.M. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981, 95:28-31.
52. Meyer H.E., Tverdal A., Falch J.A. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 1993, 137:1203-1211.
53. Nicodemus K.K., Folsom A.R. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001, 24:1192-1197.
54. Schwartz A.V., Sellmeyer D.E., Strotmeyer E.S., Tylavsky F.A., Feingold K.R., Resnick H.E., Shorr R.I., Nevitt M.C., Black D.M., Cauley J.A., Cummings S.R., Harris T.B. Diabetes and bone loss at the hip in older Black and White adults. J Bone Miner Res 2005, 20:596-603.
55. Nisbeth U., Lindh E., Ljunghall S., Backman U., Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999, 67:1218-1222.
56. Chiu M.Y., Sprague S.M., Bruce D.S., Woodle E.S., Thistlethwaite J.R., Josephson M.A. Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 1998, 9:677-683.
57. Smets Y.F., de Fijter J.W., Ringers J., Lemkes H.H., Hamdy N.A. Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. Kidney Int 2004, 66:2070-2076.
58. Gallacher S.J., Fenner J.A.K., Fisher B.M., Quin J.D., Fraser W.D., Logue F.C., Cowan R.A., Boyle I.T., MacCuish A.C. An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. Diabetic Med 1993, 10:129-133.
59. Miazgowski T., Czekalski S. A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus. Osteoporos Int 1998, 8:399-403.
60. Heap J., Murray M.A., Miller S.C., Jalili T., Moyer-Mileur L.J. Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatr 2004, 144:56-62.
61. Lettgen B., Hauffa B., Mohlmann C., Jeken C., Reiners C. Bone mineral density in children and adolescents with juvenile diabetes: Selective measurement of bone mineral density of trabecular and cortical bone using peripheral quantitative computed tomography. Horm Res 1995, 43:173-175.
62. Inaba M., Nishizawa Y., Mita K., Kumeda Y., Emoto M., Kawagishi T., Ishimura E., Nakatsuka K., Shioi A., Morii H. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int 1999, 9:525-531.
63. Inaba M., Nishizawa Y., Shioi A., Morii H. Importance of sustained high glucose condition in the development of diabetic osteopenia: Possible involvement of the polyol pathway. Osteoporos Int 1997, 7(Suppl 3):S209-S212.
64. Inaba M., Terada M., Koyama H., Yoshida O., Ishimura E., Kawagishi T., Okuno Y., Nishizawa Y., Otani S., Morii H. Influence of high glucose on 1,25-dihydroxyvitamin D3induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 1995, 10:1050-1056.
65. Inaba M., Terada M., Nishizawa Y., Shioi A., Ishimura E., Otani S., Morii H. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: Possible involvement of the polyol pathway in bone metabolism. Metabolism 1999, 48:904-909.
66. Terada M., Inaba M., Yano Y., Hasuma T., Nishizawa Y., Morii H., Otani S. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 1998, 22:17-23.
67. Campos Pastor M.M., Lopez-Ibarra P.J., Escobar-Jimenez F., Serrano Pardo M.D., Garcia-Cervigon A.G. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: A prospective study. Osteoporos Int 2000, 11:455-459.
68. Grant P.J., Stickland M.H., Bristow A.F., Clarke R.F., Wales J.K. Insulin increases somatomedin C (IGF-1) concentrations in Type 1 diabetic patients. Diabetic Med 1989, 6:245-248.
69. Hock J.M., Centrella M., Canalis E. Insulin-like growth factor-1 has independent effects on bone matrix and cell replication. Endocrinology 1988, 122:254-260.
70. Stolk R.P., Van Daele P.L., Pols H.A., Burger H., Hofman A., Birkenhager J.C., Lamberts S.W., Grobbee D.E. Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone. Bone 1996, 19(5):566-1549. [published erratum appears in].
71. Jehle P.M., Jehle D.R., Mohan S., Bohm B.O. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J Endocrinol 1998, 159:297-306.
72. McNair P. Bone mineral metabolism in human type 1 (insulindependent) diabetes mellitus. Dan Med Bull 1988, 35:109-121.
73. Shao A.-H., Wang F.G., Hu Y.-F., Zhang L.-M. Calcium metabolism and osteopathy in diabetes mellitus. Contrib Nephrol 1991, 90:212-216.
74. Klein M., Wu K., Frost H.M. The numbers of bone resorption and formation foci in rib in diabetes mellitus. Henry Ford Hosp Med Bull 1964, 12:527-536.
75. Pietschmann P., Schernthaner G., Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: Analysis of the type of diabetes and microvascular complications. Diabetologia 1988, 31:892-895.
76. Verrotti A., Basciani F., Carle F., Morgese G., Chiarelli F. Calcium metabolism in adolescents and young adults with type 1 diabetes mellitus without persistent microalbuminuria. J Endocrinol Invest 1999, 22:198-202.
77. Melchior T.M., Sorensen O.H., Thamsborg G., Sykuluski R., Storm T. Bone tissue alterations in diabetes. Tissue-Specific Metabolic Alterations in Diabetes 1990, 40-53. Karger, Basel. F. Belfiore, G.M. Molinatti, G.M. Reaven (Eds.).
78. Krakauer J., McKenna M.J., Rao D.S., Whitehouse F.W., Parfitt A.M. Low bone turnover in diabetes mellitus accounts for preservation of bone mineral density. Diabetologia 1992, 35:A192.
79. Rico H., Hernandez E.R., Diaz-Mediavilla J., Alvarez A., Martinez R., Espinos D. Treatment of multiple myeloma with nasal spray calcitonin: A histomorphometric and biochemical study. Bone Miner 1990, 8:231-237.
80. el Miedany Y.M., el Gaafary S., el Baddini M.A. Osteoporosis in older adults with non-insulin-dependent diabetes mellitus: Is it sex related?. Clin Exp Rheumatol 1999, 17:561-567.
81. Erbagci A.B., Araz M., Erbagci A., Tarakcioglu M., Namiduru E.S. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin Biochem 2002, 35:263-268.
82. Mauricio D., Mandrup-Poulsen T., Nerup J. Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: A therapeutic perspective. Diabetes Metab Rev 1996, 12:57-68.
83. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 2001, 358:1500-1503.
84. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. Diabetologia 1999, 42:51-54.
85. Pozzilli P., Manfrini S., Crino A., Picardi A., Leomanni C., Cherubini V., Valente L., Khazrai M., Visalli N. Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2005, 37:680-683.
86. Pittas A.G., Dawson-Hughes B., Li T., Van Dam R.M., Willett W.C., Manson J.E., Hu F.B. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006, 29:650-656.
87. Liu S., Song Y., Ford E.S., Manson J.E., Buring J.E., Ridker P.M. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S women. Diabetes Care 2005, 28:2926-2932.
88. Need A.G., O'Loughlin P.D., Horowitz M., Nordin B.E. Relationship between fasting serum glucose, age body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol (Oxf) 2005, 62:738-741.
89. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004, 27:2813-2818.
90. Baynes K.C., Boucher B.J., Feskens E.J., Kromhout D. Vitamin D glucose tolerance and insulinaemia in elderly men. Diabetologia. Diabetologia 1997, 40(7):870-1347. [published erratum appears in].
91. Chiu K.C., Chu A., Go V.L., Saad M.F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004, 79:820-825.
92. McDermott M.F., Ramachandran A., Ogunkolade B.W., Aganna E., Curtis D., Boucher B.J., Snehalatha C., Hitman G.A. Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians. Diabetologia 1997, 40:971-975.
93. Ogunkolade B.W., Boucher B.J., Prahl J.M., Bustin S.A., Burrin J.M., Noonan K., North B.V., Mannan N., McDermott M.F., DeLuca H.F., Hitman G.A. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 2002, 51:2294-2300.
94. Malecki M.T., Frey J., Moczulski D., Klupa T., Kozek E., Sieradzki J. Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population. Exp Clin Endocrinol Diabetes 2003, 111:505-509.
95. Turpeinen H., Hermann R., Vaara S., Laine A.P., Simell O., Knip M., Veijola R., Ilonen J. Vitamin D receptor polymorphisms: No association with type 1 diabetes in the Finnish population. Eur J Endocrinol 2003, 149:591-596.
96. Baier L.J., Dobberfuhl A.M., Pratley R.E., Hanson R.L., Bogardus C. Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. J Clin Endocrinol Metab 1998, 83:2993-2996.
97. Malecki M.T., Klupa T., Wanic K., Cyganek K., Frey J., Sieradzki J. Vitamin D binding protein gene and genetic susceptibility to type 2 diabetes mellitus in a Polish population. Diabetes Res Clin Pract 2002, 57:99-104.
98. Hampson G., Evans C., Petitt R.J., Evans W.D., Woodhead S.J., Peters J.R., Ralston S.H. Bone mineral density, collagen type 1 alpha 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 1998, 41:1314-1320.
99. Keegan T.H., Schwartz A.V., Bauer D.C., Sellmeyer D.E., Kelsey J.L. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: The fracture intervention trial. Diabetes Care 2004, 27:1547-1553.
100. Tavill A.S. Diagnosis and management of hemochromatosis. Hepatology 2001, 33:1321-1328.
101. Delbarre F. L'osteoporose des hemochromatoses. Semin Hop Paris 1960, 36:3279-3295.
102. Diamond T., Stiel D., Posen S. Osteoporosis in hemochromatosis: Iron excess, gonadal deficiency or other factors?. Ann Intern Med 1989, 110:430-436.
103. Pawlotsky Y., Lacien Y., Roudier G., Hany Y., Louboutin J.Y., Ferrand B., Bourel M. Histomorphometrie osseuse et manifestations osteo-articulaires de l'hemochromatose idiopathique. Rev Rhum Mal Osteoartic 1979, 46:91-99.
104. Sinigaglia L., Fargion S., Fracanzani A.L., Binelli L., Battafarano N., Varenna M., Piperno A., Fiorelli G. Bone and joint involvement in genetic hemochromatosis: Role of cirrhosis and iron overload. J Rheumatol 1997, 24:1809-1813.
105. Guggenbuhl P., Deugnier Y., Boisdet J.F., Rolland Y., Perdriger A., Pawlotsky Y., Chales G. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005, 16:1809-1814.
106. Conte D., Caraceni M.P., Duriez J., Mandelli C., Corghi E., Cesana M., Ortolani S., Bianchi P.A. Bone involvement in primary hemochromatosis and alcoholic cirrhosis. Am J Gastroenterol 1989, 84:1231-1234.
107. Czink E., Horvath C., Malek A.A., Siklosi G. Is dehydroepiandrosterone sulfate a possible pathogenetic factor in osteopenia of patients with iron overload?. Haematologia 1991, 24:47-56.
108. Oerter K.E., Kamp G.A., Munson P.J., Nienhuis A.W., Cassorla F.G., Manasco P.K. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab 1993, 76:357-361.
109. Kaplan M.M. Primary biliary cirrhosis, Wilson's disease hemochromatosis, and other metabolic and fibrotic liver diseases. Internal Medicine 1994, 622-624. Mosby, St. Louis, MO. J.H. Stein (Ed.).
110. Diamond T., Stiel D., Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res 1991, 6:39-43.
111. Angelopoulos N.G., Goula A.K., Papanikolaou G., Tolis G. Osteoporosis in HFE2 juvenile hemochromatosis. A case report and review of the literature. Osteoporos Int 2006, 17:150-155.
112. Albright F., Reifenstein E.C. The Parathyroid Glands and Metabolic Bone Disease: Selected Studies 1948, Williams and Wilkins, Baltimore.
113. Riggs L., Randall R.V., Wahner H.W., Jowsey J., Kelly P.J., Singh M. The nature of metabolic bone disorder in acromegaly. J Clin Endocrinol Metab 1972, 34:911-918.
114. Seeman E., Wahner H.W., Offord K.P., Kumar R., Johnson W.J., Riggs B.L. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest 1982, 69:1302-1309.
115. Jockenhovel F., Rohrbach S., Deggerich S., Reinwein D., Reiners C. Differential presentation of cortical and trabecular peripheral bone mineral density in acromegaly. Eur J Med Res 1996, 1:377-382.
116. Diamond T., Nery L., Posen S. Spinal and peripheral bone mineral densities in acromegaly: The effects of excess growth hormone and hypogonadism. Ann Intern Med 1989, 111:567-573.
117. Ezzat S., Melmed S., Endres D., Eyre D., Singer F.R. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993, 76:1452-1457.
118. Lesse G.P., Fraser W.D., Farquharson R., Hipkin L., Vora J.P. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol (Oxf) 1998, 48:59-65.
119. Bonadonna S., Mazziotti G., Nuzzo M., Bianchi A., Fusco A., De Marinis L., Giustina A. Increased prevalence of radiological spinal deformities in active acromegaly: A crosssectional study in postmenopausal women. J Bone Miner Res 2005, 20:1837-1844.
120. Scillitani A., Chiodini I., Carnevale V., Giannatempo G.M., Frusciante V., Villella M., Pileri M., Guglielmi G., Di Giorgio A., Modoni S., Fusilli S., Di Cerbo A., Liuzzi A. Skeletal involvement in female acromegalic subjects: The effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 1997, 12:1729-1736.
121. Ueland T. Bone metabolism in relation to alterations in systemic growth hormone. Growth Horm IGF Res 2004, 14:404-417.
122. Stracke H., Schulz A., Moeller D., Rossol S., Schatz H. Effect of growth hormone on osteoblasts and demonstration of somatomedin-C/IGF-I in bone organ culture. Acta Endocrinol 1984, 107:16-24.
123. Andreassen T.T., Oxlund H. The effects of growth hormone on cortical and cancellous bone. J Musculoskelet Neuronal Interact 2001, 2:49-58.
124. Canalis E. Effect of insulin-like growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest 1980, 66:709-719.
125. Canalis E., McCarthy T.L., Centrella M. The role of growth factors in skeletal remodeling. Endocrinol Metab Clin North Am 1989, 18:903-918.
126. Johansen J.S., Pedersen S.A., Jorgensen J.O.L., Riis B.J., Christiansen C., Christiansen J.S., Skakkeback N.D. Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults. J Clin Endocrinol Metab 1990, 70:916-919.
127. de la Piedra C., Carbo E., Larranaga J., Castro N., Horcajada C., Rapado A., Herrera-Pombo J.L., Carbo E. Correlation among plasma osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcif Tissue Int 1988, 43:44-45.
128. Terzolo M., Piovesan A., Osella G., Pia A., Reimondo G., Pozzi C., Raucci C., Torta M., Paccotti P., Angeli A. Serum levels of bone Gla protein (osteocalcin BGP) and carboxyterminal propeptide of type 1 procollagen (PICP) in acromegaly: Effects of long-term octreotide treatment. Calcif Tissue Int 1993, 52:188-191.
129. Legovini P., De Menis E., Breda F., Billeci D., Carteri A., Pavan P., Conte N. Long-term effects of octreotide on markers of bone metabolism in acromegaly: Evidence of increased serum parathormone concentrations. J Endocrinol Invest 1997, 20:434-438.
130. White H.D., Ahmad A.M., Durham B.H., Chandran S., Patwala A., Fraser W.D., Vora J.P. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 2006, 91:913-919.
131. Ueland T., Bollerslev J., Hansen T.B., Ebbesen E.N., Mosekilde L., Brixen K., Flyvbjerg A., Djoseland O. Increased cortical bone content of insulin-like growth factors in acromegalic patients. J Clin Endocrinol Metab 1999, 84:123-127.
132. Halse J., Melsen F., Mosekilde L. Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol 1981, 97:18-22.
133. Diebold J., Batge B., Stein H., Muller-Esch G., Muller P.K., Lohrs U. Osteoporosis in longstanding acromegaly: Characteristic changes of vertebral trabecular architecture and bone matrix composition. Virchow Archiv Pathol Anat 1991, 419:209-215.
134. Delling G.R., Schulz A. Bone cells and remodeling surfaces in acromegaly. Calcif Tissue Res (Suppl) 1977, 22:255-259.
135. Beutler G.G. Gaucher Disease 2001, McGraw-Hill, New York.
136. Pastores G.M., Meere P.A. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol 2005, 17:70-78.
137. Hermann G., Goldblatt J., Levy R.N., Goldsmith S.J., Desnick R.J., Grabowski G.A. Gaucher's disease type 1: Assessment of bone involvement by CT and scintigraphy. AJR Am J Roentgenol 1986, 147:943-948.
138. Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., Rosenbloom B.E., Scott C.R., Wappner R.S., Weinreb N.J., Zimran A. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000, 160:2835-2843.
139. Wiesner L., Niggemeyer O., Kothe R., Meiss L. Severe pathologic compression of three consecutive vertebrae in Gaucher's disease: A case report and review of the literature. Eur Spine J 2003, 12:97-99.
140. Katz K., Sabato S., Horev G., Cohen I.J., Yosipovitch Z. Spinal involvement in children and adolescents with Gaucher disease. Spine 1993, 18:332-335.
141. Grabowski G.A., Andria G., Baldellou A., Campbell P.E., Charrow J., Cohen I.J., Harris C.M., Kaplan P., Mengel E., Pocovi M., Vellodi A. Pediatric non-neuronopathic Gaucher disease: Presentation diagnosis and assessment. Consensus statements. Eur J Pediatr 2004, 163:58-66.
142. Itzchaki M., Lebel E., Dweck A., Patlas M., Hadas-Halpern I., Zimran A., Elstein D. Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy. Acta Orthop Scand 2004, 75:641-653.
143. Maas M., Hollak C.E., Akkerman E.M., Aerts J.M., Stoker J., Den Heeten G.J. Quantification of skeletal involvement in adults with type I Gaucher's disease: Fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 2002, 179:961-965.
144. Pastores G.M., Wallenstein S., Desnick R.J., Luckey M.M. Bone density in Type 1 Gaucher disease. J Bone Miner Res 1996, 11:1801-1807.
145. Grabowski G.A. Recent clinical progress in Gaucher disease. Curr Opin Pediatr 2005, 17:519-524.
146. Ciana G., Addobbati R., Tamaro G., Leopaldi A., Nevyjel M., Ronfani L., Vidoni L., Pittis M.G., Bembi B. Gaucher disease and bone: Laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 2005, 28:723-732.
147. Allen M.J., Myer B.J., Khokher A.M., Rushton N., Cox T.M. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: Increased release of interleukin-6 and interleukin-10. QJM 1997, 90:19-25.
148. Ciana G., Martini C., Leopaldi A., Tamaro G., Katouzian F., Ronfani L., Bembi B. Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 2003, 72:185-189.
149. Drugan C., Jebeleanu G., Grigorescu-Sido P., Caillaud C., Craciun A.M. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 2002, 28:13-20.
150. Fiore C.E., Barone R., Pennisi P., Pavone V., Riccobene S. Bone ultrasonometry, bone density and turnover markers in type 1 Gaucher disease. J Bone Miner Metab 2002, 20:34-38.
151. Zimran A., Bashkin A., Elstein D., Rudensky B., Rotstein R., Rozenblat M., Mardi T., Zeltser D., Deutsch V., Shapira I., Berliner S. Rheological determinants in patients with Gaucher disease and internal inflammation. Am J Hematol 2004, 75:190-194.
152. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991, 324:1464-1470.
153. Weinreb N.J., Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., Rosenbloom B.E., Scott C.R., Wappner R.S., Zimran A. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am J Med 2002, 113:112-119.
154. Perez-Calvo J.I., Roca-Espiau M., Pastores G.M. Bone crisis in stable Gaucher's disease. QJM 2005, 98:916-918.
155. Pastores G.M., Hermann G., Norton K.I., Lorberboym M., Desnick R.J. Regression of skeletal changes in type 1 Gaucher disease with enzyme replacement therapy. Skeletal Radiol 1996, 25:485-488.
156. Pastores G.M., Hermann G., Norton K., Desnick R.J. Resolution of a proximal humeral defect in type-1 Gaucher disease by enzyme replacement therapy. Pediatr Radiol 1995, 25:486-487.
157. El-Beshlawy A., Ragab L., Youssry I., Yakout K., El-Kiki H., Eid K., Mansour I.M., El-Hamid S.A., Yang M., Mistry P.K. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 2006, 29:92-98.
158. Lebel E., Dweck A., Foldes A.J., Golowa Y., Itzchaki M., Zimran A., Elstein D. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 2004, 22:597-601.
159. Wenstrup R.J., Bailey L., Grabowski G.A., Moskovitz J., Oestreich A.E., Wu W., Sun S. Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004, 104:1253-1257.
160. Ciana G., Cuttini M., Bembi B. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med 1997, 337:712.
161. Rudzki Z., Okon K., Machaczka M., Rucinska M., Papla B., Skotnicki A.B. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease-A histological study. Eur J Haematol 2003, 70:273-281.
162. Schiffmann R., Mankin H., Dambrosia J.M., Xavier R.J., Kreps C., Hill S.C., Barton N.W., Rosenthal D.I. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 2002, 28:288-296.
163. Poll L.W., Koch J.A., Willers R., Aerts H., Scherer A., Haussinger D., Modder U., vom Dahl S. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 2002, 28:209-220.
164. Albright F., Henneman P., Benedict P.H., Forbes A.P. Idiopathic hypercalciuria: A preliminary report. Proc R Soc Med 1953, 46:1077-1081.
165. Frick K., Bushinsky D. Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol 2003, 14:1082-1095.
166. Levy F.L., Adams-Huet B., Pak C.Y. Ambulatory evaluation of nephrolithiasis: An update of a 1980 protocol. Am J Med 1995, 98:50-59.
167. Moe O.W., Bonny O. Genetic hypercalciuria. J Am Soc Nephrol 2005, 16:729-745.
168. Giannini S., Nobile M., Sella S., Dalle Carbonare L. Bone disease in primary hypercalciuria. Crit Rev Clin Lab Sci 2005, 42:229-248.
169. Pak C.Y., Oata M., Lawrence E.C., Snyder W. The hypercalciurias. Causes, parathyroid functions, and diagnostic criteria. J Clin Invest 1974, 54:387-400.
170. Deutschmann H.A., Weger M., Weger W., Kotanko P., Deutschmann M.J., Skrabal F. Search for occult secondary osteoporosis: Impact of identified possible risk factors on bone mineral density. J Intern Med 2002, 252:389-397.
171. Giannini S., Nobile M., Dalle Carbonare L., Lodetti M.G., Sella S., Vittadello G., Minicuci N., Crepaldi G. Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol 2003, 149:209-213.
172. Peris P., Guanabens N., Martinez de Osaba M.J., Monegal A., Alvarez L., Pons F., Ros I., Cerda D., Munoz-Gomez J. Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum 2002, 32:64-70.
173. Tannenbaum C., Clark J., Schwartzman K., Wallenstein S., Lapinski R., Meier D., Luckey M. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002, 87:4431-4437.
174. Heilberg I.P., Weisinger J.R. Bone disease in idiopathic hypercalciuria. Curr Opin Nephrol Hypertens 2006, 15:394-402.
175. Melton 3rd L.J., Crowson C.S., Khosla S., Wilson D.M., O'Fallon W.M. Fracture risk among patients with urolithiasis: A population-based cohort study. Kidney Int 1998, 53:459-464.
176. Lauderdale D.S., Thisted R.A., Wen M., Favus M.J. Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res 2001, 16:1893-1898.
177. Penido M.G., Lima E.M., Marino V.S., Tupinamba A.L., Franca A., Souto M.F. Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis. Pediatr Nephrol 2003, 18:133-139.
178. Garcia-Nieto V., Navarro J.F., Monge M., Garcia-Rodriguez V.E. Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephron Clin Pract 2003, 94:89-93.
179. Freundlich M., Alonzo E., Bellorin-Font E., Weisinger J.R. Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant 2002, 17:1396-1401.
180. Coe F.L., Evan A., Worcester E. Kidney stone disease. J Clin Invest 2005, 115:2598-2608.
181. Pak C.Y., Britton F., Peterson R., Ward D., Northcutt C., Breslau N.A., McGuire J., Sakhaee K., Bush S., Nicar M., Norman D.A., Peters P. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 1980, 69:19-30.
182. Bushinsky D.A. Genetic hypercalciuric stone-forming rats. Curr Opin Nephrol Hypertens 1999, 8:479-488.
183. Vezzoli G., Rubinacci A., Bianchin C., Arcidiacono T., Giambona S., Mignogna G., Fochesato E., Terranegra A., Cusi D., Soldati L. Intestinal calcium absorption is associated with bone mass in stone-forming women with idiopathic hypercalciuria. Am J Kidney Dis 2003, 42:1177-1183.
184. Pacifici R., Rothstein M., Rifas L., Lau K.H., Baylink D.J., Avioli L.V., Hruska K. Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. J Clin Endocrinol Metab 1990, 71:138-145.
185. Misael da Silva A.M., dos Reis L.M., Pereira R.C., Futata E., Branco-Martins C.T., Noronha I.L., Wajchemberg B.L., Jorgetti V. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002, 57:183-191.
186. Weisinger J.R., Alonzo E., Bellorin-Font E., Blasini A.M., Rodriguez M.A., Paz-Martinez V., Martinis R. Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 1996, 49:244-250.
187. Ghazali A., Fuentes V., Desaint C., Bataille P., Westeel A., Brazier M., Prin L., Fournier A. Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997, 82:32-38.
188. Malluche H.H., Tschoepe W., Ritz E., Meyer-Sabellek W., Massry S.G. Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980, 50:654-658.
189. Curhan G.C., Willett W.C., Rimm E.B., Stampfer M.J. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993, 328:833-838.
190. Martini L.A., Cuppari L., Colugnati F.A., Sigulem D.M., Szejnfeld V.L., Schor N., Heilberg I.P. High sodium chloride intake is associated with low bone density in calcium stone-forming patients. Clin Nephrol 2000, 54:85-93.
191. Kerstetter J.E., O'Brien K.O., Insogna K.L. Dietary protein, calcium metabolism, and skeletal homeostasis revisited. Am J Clin Nutr 2003, 78:584S-592S.
192. Lau E.M., Leung P.C., Kwok T., Woo J., Lynn H., Orwoll E., Cummings S., Cauley J. The determinants of bone mineral density in Chinese men-Results from Mr. Os (Hong Kong) the first cohort study on osteoporosis in Asian men. Osteoporos Int 2006, 17:297-303.
193. Rejnmark L., Vestergaard P., Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 2005, 76:167-175.
194. Schoofs M.W., van der Klift M., Hofman A., de Laet C.E., Herings R.M., Stijnen T., Pols H.A., Stricker B.H. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003, 139:476-482.
195. Steiniche T., Mosekilde L., Christensen M.S., Melsen F. Histomorphometric analysis of bone in idiopathic hypercalciuria before and after treatment with thiazide. Apmis 1989, 97:302-308.
196. Bushinsky D.A. Calcium nephrolithiasis. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2006, 458-459. American Society for Bone and Mineral Research, Washington, D.C. M.J. Favus (Ed.).
197. Sakhaee K., Maalouf N.M., Abrams S.A., Pak C.Y. Effects of potassium alkali and calcium supplementation on bone turnover in postmenopausal women. J Clin Endocrinol Metab 2005, 90:3528-3533.
198. Griffith G.C., Silverglade A. Symposium on heparin. Am J Cardiol 1964, 14:1-2.
199. Griffith G.C., Nichols G., Asher J.D., Flanagan B. Heparin osteoporosis. JAMA 1965, 193:91-95.
200. Jaffe M.D., Willis P.W. Multiple fractures associated with long-term heparin therapy. JAMA 1965, 193:152-154.
201. Marcus R. Secondary forms of osteoporosis. Disorders of Bone and Mineral Metabolism 1992, 902-903. Raven Press, New York. F.L. Coe, M.J. Favus (Eds.).
202. Sackler J.P., Liu L. Heparin-induced osteoporosis. Br J Radiol 1973, 46:548-550.
203. Aarskog D., Aksnes L., Lehmann V. Low 1,25-dihydroxyvitamin D in heparin-induced osteopenia. Lancet 1980, ii:650-651.
204. Wise P.H., Hall A.J. Heparin-induced osteopenia in pregnancy. BMJ 1980, 281:110-111.
205. Squires J.W., Pinch L.W. Heparin-induced spinal fractures. J Am Med Assoc 1979, 241:2417-2418.
206. Megard M., Cuche M., Grapeloux A., Bojoly C., Meunier P.J. Osteoporose de l'heparinotherapie. Analyse histomorphometrique de la biopsie osseuse. Une observation. Nous Press Med 1982, 11:261-264.
207. Lequesne M., Lamotte J., Foures N. Osteoporose del'heparinotherapie, osteoporose de la mastocytose. L'actualite rheumatologique, in L'actualite rheumatologique 1982, 105-115. Francaise, Paris. S.D. Seze, A. Ryckewaert, M.F. Kahn, C. Guerin (Eds.).
208. Bardin T., Lequesne M. The osteoporosis of heparinotherapy and systemic mastocytosis. Clin Rheumatol 1989, 8:119-123.
209. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265-1270.
210. Dahlman T., Lindvall N., Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: A radiological study post partum. Br J Obstet Gynaecol 1990, 97:221-228.
211. Rupp W.M., McCarthy H.B., Rohde T.D., Blackshear P.J., Goldenberg F.J., Buchwald H. Risk of osteoporosis in patients treated with long-term intravenous heparin therapy. Curr Surg 1982, 39:419-422.
212. Ginsberg J.S., Kowalchuk C.T., Hirsch J., Brill-Edwards P., Burrows R., Coates G., Webber C. Heparin effect on bone density. Thromb Haemostasis 1990, 64:286-289.
213. DeSwiet M., Dorrington P.W., Fidler J., Horsman A., Katz D., Letsky E., Peacock M., Wise P.H. Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynecol 1983, 90:1129-1134.
214. Barbour L.A., Kick S.D., Steiner J.F., LoVerde M.E., Heddleston L.N., Lear J.L., Baron A.E., Barton P.L. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994, 170:862-869.
215. Dahlman T.C., Sjoberg H.E., Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994, 170:1315-1320.
216. Vijgh W.J.F.v.d., Kruik A.B.J., Jongen M.J.M., Lips P., Netelenbos J.C. Inhibition of 25(OH)D 1a-hydroxylase in kidney homogenates of Japanese quail by heparin. Netelenbos Calcif Tissue Int 1983, 35:192. [Abstract].
217. Mutoh S., Takeshita N., Yoshino T., Yamaguchi I. Characterization of heparin-induced osteopenia in rats. Endocrinology 1993, 133:2743-2748.
218. Aarskog D., Aksnes L., Markestad T., Ulstein M., Sagen N. Heparin-induced inhibition of 1,25-dihydroxyvitamin D formation. Am J Obstet Gynecol 1984, 148:1141-1142.
219. Goldhaber P. Heparin enhancement factors stimulating bone resorption in tissue culture. Science 1965, 147:407-408.
220. Asher J.D., Nichols G. Heparin stimulation of bone collagenase activity. Fed Proc 1965, 24:211.
221. Sakamoto S., Sakamoto M. Bone collagenase, osteoblasts and cell-mediated bone resorption. J Bone Miner Res 1986, 4:49-102.
222. Shaughnessy S.G., Hirsh J., Bhandari M., Muir J.M., Young E., Weitz J.I. A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 1999, 93:1231-1236.
223. Thompson R.C. Heparin osteoporosis: An experimental model using rats. J Bone Jt Surg 1973, 55A:606-612.
224. Zimran A., Shilo S., Fisher D., Bab I. Histomorphometric evaluation of reversible heparin-induced osteoporosis in pregnancy. Arch Intern Med 1986, 146:386-388.
225. Ginsberg J.S., Hirsh J. Optimum use of anticoagulants in pregnancy. Drugs 1988, 36:505-512.
226. Many A., Pauzner R., Carp H., Langevitz P., Martinowitz U. Treatment of patients with antiphospholipid antibodies during pregnancy. Am J Reprod Immunol 1992, 28:216-218.
227. Greer I.A. Anticoagulants in pregnancy. J Thromb Thrombolysis 2006, 21:57-65.
228. Matzsch T., Bergvuist D., Hedner U., Nilsson B. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemostasis 1990, 63:505-509.
229. Muir J.M., Hirsh J., Weitz J.I., Andrew M., Young E., Shaughnessy S.G. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997, 89:3236-3242.
230. Folwarczna J., Janiec W., Sliwinski L. Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost 2004, 92:940-946.
231. Handschin A.E., Trentz O.A., Hoerstrup S.P., Kock H.J., Wanner G.A., Trentz O. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005, 92:177-183.
232. Sivakumaran M., Ghosh K., Zaidi Y., Hutchinson R.M. Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient. Clin Lab Haematol 1996, 18:55-57.
233. Greer I.A., Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 2005, 106:401-407.
234. Wawrzynska L., Tomkowski W.Z., Przedlacki J., Hajduk B., Torbicki A. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003, 33:64-67.
235. Pettila V., Leinonen P., Markkola A., Hiilesmaa V., Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002, 87:182-186.
236. Casele H.L., Laifer S.A. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000, 9:122-125.
237. Price P.A., Williamson M.K. Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone. J Biol Chem 1981, 256:12754-12759.
238. Obrant K.J., Kakonen S.M., Astermark J., Lilja H., Lovgren T., Akesson K., Pettersson K. The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects. J Bone Miner Res 1999, 14:555-560.
239. Hauschka P.V., Reid M.L. Vitamin K dependence of a calcium binding protein containing gamma-carboxyglutamic acid in chicken bone. J Biol Chem 1978, 253:9063-9068.
240. Pastoureau P., Vergnaud P., Meunier P.J., Delmas P.D. Osteopenia and bone-remodeling abnormalities in warfarintreated lambs. J Bone Miner Res 1993, 8:1417-1426.
241. Simon R.R., Beaudin S.M., Johnston M., Walton K.J., Shaughnessy S.G. Long-term treatment with sodium warfarin results in decreased femoral bone strength and cancellous bone volume in rats. Thromb Res 2002, 105:353-358.
242. Hall J., Pauli R.M., Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980, 68:122-140.
243. Barnes C., Newall F., Ignjatovic V., Wong P., Cameron F., Jones G., Monagle P. Reduced bone density in children on long-term warfarin. Pediatr Res 2005, 57:578-581.
244. Gage B.F., Birman-Deych E., Radford M.J., Nilasena D.S., Binder E.F. Risk of osteoporotic fracture in elderly patients taking warfarin: Results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006, 166:241-246.
245. Jamal S.A., Browner W.S., Bauer D.C., Cummings S.R. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med 1998, 128:829-832.
246. Werkheiser W.C. Specific binding of 4-amino folic acid analogs by folic acid reductase. J Biol Chem 1961, 236:888-893.
247. Mazanec D.J., Grisanti J.M. Drug-induced osteoporosis. Cleveland Clin J Med 1989, 56:297-303.
248. O'Regan S., Melhorn D.K., Newman A.J. Methotrexateinduced bone pain in childhood leukemia. Am J Dis Child 1973, 126:489-490.
249. Regab A.H., Frech R.S., Vietti T.J. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 1970, 25:580-585.
250. Schwartz A.M., Leonidas J.C. Methotrexate osteopathy. Skeletal Radiol 1984, 11:13-16.
251. Stanisavljevic S., Babcock A.L. Fractures in children treated with methotrexate for leukemia. Clin Orthop Relat Res 1977, 125:139-144.
252. Scalone J., Bowen J.R. Methotrexate osteopathy: Case report. Contemp Orthop 1988, 17:46-49.
253. Jones G., Sambrook P.N. Drug-induced disorders of bone metabolism. Incidence, management and avoidance. Drug Safety 1994, 10:480-489.
254. Kruse R. Osteopathien bei antiepiliptscher langzeit-Therapie. Monatsschr Kinderheilkd 1968, 116:378-380.
255. Nesbit M., Krivit W., Heyn R., Sharp H. Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems. Cancer 1976, 37:1048-1054.
256. Gnudi S., Butturini L., Ripamonti C., Avella M., Baci G. The effects of methotrexate on bone. A densitometric study conducted on 59 patients with methotrexate administered at different doses. Ital J Orthop Traumatol 1988, 14:227-231.
257. Bianchi M.L., Cimaz R., Galbiati E., Corona F., Cherubini R., Bardare M. Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. Osteoporos Int 1999, 10:20-25.
258. Holzer G., Krepler P., Koschat M.A., Grampp S., Dominkus M., Kotz R. Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg Br 2003, 85:231-237.
259. Tillmann V., Darlington A.S., Eiser C., Bishop N.J., Davies H.A. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukemia. J Bone Miner Res 2002, 17:1073-1080.
260. Warner J.T., Evans W.D., Webb D.K., Bell W., Gregory J.W. Relative osteopenia after treatment for acute lymphoblastic leukemia. Pediatr Res 1999, 45:544-551.
261. Lequin M.H., van der Shuis I.M., Van Rijn R.R., Hop W.C., van ven Huevel-Eibrink M.M., MuinckKeizer-Schrama S.M., van Kuijk C. Bone mineral assessment with tibial ultrasonometry and dual-energy x-ray absorptiometry in long-term survivors of acute lymphoblastic leukemia in childhood. J Clin Densitom 2002, 5:167-173.
262. Nysom K., Holm K., Hertz H., Muller J., Michaelsen K.F., Molgaard C. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol 2001, 19:2970-2971.
263. di Munno O., Mazzantini M., Sinigaglia L., Bianchi G., Minisola G., Muratore M., la Corte R., di Matteo L., Canesi B., Caminiti M., Broggini M., Adami S. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: Results from a multicenter cross-sectional study. J Rheumatol 2004, 31:1305-1309.
264. Minaur N.J., Kounali D., Vedi S., Compston J.E., Beresford J.N., Bhalla A.K. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002, 41:741-749.
265. Mazzantini M., Di Munno O., Incerti-Vecchi L., Pasero G. Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate. Clin Exp Rheumatol 2000, 18:327-331.
266. Cranney A.B., McKendry R.J., Wells G.A., Ooi D.S., Kanigsberg N.D., Kraag G.R., Smith C.D. The effect of low dose methotrexate on bone density. J Rheumatol 2001, 28:2395-2399.
267. Arai K., Hanyu T., Sugitani H., Murai T., Fujisawa J., Nakazono K., Kondo N., Endo N. Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: A cross-sectional and longitudinal study. J Bone Miner Metab 2006, 24:118-124.
268. Preston S.J., Diamond T., Scott A., Laurent M.R. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993, 52:582-585.
269. Singwe M., Le Gars L., Karneff A., Prier A., Kaplan G. Multiple stress fractures in a scleroderma patient on methotrexate therapy. Rev Rhum Engl Ed 1998, 65:508-510.
270. Thomas L.B., Forkner C.E., Frei I.E., Besse J.B.E., Stabenau J.R. The skeletal lesions of acute leukemia. Cancer 1961, 14:608-621.
271. Waisman H.A., Harvey R.A. Radiological evidence of growth in children with acute leukemia treated with folic acid antagonists. Radiology 1954, 62:61-64.
272. Nevinny H.B., Krent M.J., Moore E.W. Metabolic studies on the effects of methotrexate. Metabolism 1965, 14:135-139.
273. Friedlander G.E., Tross R.B., Doganis A.C., Kirkwood J.M., Baron R. Effects of chemotherapeutic agents on bone. 1. Short-term methotrexate and doxorubicin (Adriamycin) treatment in a rat model. J Bone Jt Surg 1984, 66:602-607.
274. May K.P., West S.G., McDermott M.T., Huffer W.E. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 1994, 37:201-206.
275. Cegiela U., Sliwinski L., Kaczmarczyk-Sedlak I., Folwarczna J. In vivo effects of high-dose methotrexate on bone remodeling in rats. Pharmacol Rep 2005, 57:504-514.
276. Minaur N.J., Jefferiss C., Bhalla A.K., Beresford J.N. Methotrexate in the treatment of rheumatoid arthritis. I. In vitro effects on cells of the osteoblast lineage. Rheumatology (Oxford) 2002, 41:735-740.
277. Yilmaz L., Ozoran K., Gunduz O.H., Ucan H., Yucel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 2001, 20:65-69.
278. Hauser W.A., Annegers J.F., Kurland L.T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993, 34:453-468.
279. Pack A.M. Bone disease in epilepsy. Curr Neurol Neurosci Rep 2004, 4:329-334.
280. Pack A.M., Morrell M.J. Epilepsy and bone health in adults. Epilepsy Behav 2004, 5(Suppl 2):S24-S29.
281. Vestergaard P., Tigaran S., Rejnmark L., Tigaran C., Dam M., Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999, 99:269-275.
282. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
283. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., Vogt T.M. Risk factors for hip fracture in White women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995, 332:767-773.
284. Desai K.B., Ribbans W.J., Taylor G.J. Incidence of five common fracture types in an institutional epileptic population. Injury 1996, 27:97-100.
285. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., De Laet C., Jonsson B. Mortality after osteoporotic fractures. Osteoporos Int 2004, 15:38-42.
286. Hahn T.J. Steroid and drug-induced osteopenia. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 1993, 252-255. Raven Press, New York. M.J. Favus (Ed.).
287. Dent C.E., Richens A., Rowe D.J., Stamp T.C. Osteomalacia with long-term anticonvulsant therapy in epilepsy. BMJ 1970, 4:69-72.
288. Hoikka V., Savolainen K., Alhava E.M., Sivenius J., Karjalainen P., Repo A. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand 1981, 64:122-131.
289. Hunter J., Maxwell J.D., Stewart D.A., Parsons V., Williams R. Altered calcium metabolism in epileptic children on anticonvulsants. BMJ 1971, 4:202-204.
290. Farhat G., Yamout B., Mikati M.A., Demirjian S., Sawaya R., El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002, 58:1348-1353.
291. Stephen L.J., McLellan A.R., Harrison J.H., Shapiro D., Dominiczak M.H., Sills G.J., Brodie M.J. Bone density and antiepileptic drugs: A case-controlled study. Seizure 1999, 8:339-342.
292. Sheth R.D., Wesolowski C.A., Jacob J.C., Penney S., Hobbs G.R., Riggs J.E., Bodensteiner J.B. Effect of carbamazepine and valproate on bone mineral density [see comments]. J Pediatr 1995, 127:256-262.
293. Valinaki M.J., Tiihonen M., Laitinen K., Tahtela R., Karkkainen M., Lamberg-Allardt C., Makela P., Tunninen R. Bone mineral density measured by dual-energy xray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994, 9:631-637.
294. Sato Y., Kondo I., Ishida S., Motooka H., Takayama K., Tomita Y., Maeda H., Satoh K. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445-449.
295. Andress D.L., Ozuna J., Tirschwell D., Grande L., Johnson M., Jacobson A.F., Spain W. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002, 59:781-786.
296. Mosekilde L., Melsen F. Dynamic differences in trabecular bone remodeling between patients after jejuno-ileal bypass for obesity and epileptic patients receiving anticonvulsant therapy. Metab Bone Dis Relat Res 1980, 2:77-82.
297. Weinstein R.S., Bryce G.F., Sappington L.J., King D.W., Gallagher B.B. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984, 58:1003-1009.
298. Christiansen C., Rodbro P., Lund P. Incidence of anticonvulsant osteomalacia and effect of vitamin D: Controlled therapeutic trial. BMJ 1973, 4:695-701.
299. Kinjo M., Setoguchi S., Schneeweiss S., Solomon D.H. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005, 118:1414.
300. Kubota F., Kifune A., Shibata N., Akata T., Takeuchi K., Takahashi S., Ohsawa M., Takama F. Bone mineral density of epileptic patients on long-term antiepileptic drug therapy: A quantitative digital radiography study. Epilepsy Res 1999, 33:93-97.
301. Kulak C.A., Borba V.Z., Bilezikian J.P., Silvado C.E., Paola L., Boguszewski C.L. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr 2004, 62:940-948.
302. Boluk A., Guzelipek M., Savli H., Temel I., Ozisik H.I., Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004, 50:93-97.
303. Chung S., Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994, 16:382-385.
304. Tsukahara H., Kimura K., Todoroki Y., Ohshima Y., Hiraoka M., Shigematsu Y., Tsukahara Y., Miura M., Mayumi M. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002, 44:247-253.
305. Petty S.J., Paton L.M., O'Brien T.J., Makovey J., Erbas B., Sambrook P., Berkovic S.F., Wark J.D. Effect of antiepileptic medication on bone mineral measures. Neurology 2005, 65:1358-1365.
306. Sheth R.D. Bone health in pediatric epilepsy. Epilepsy Behav 2004, 5(Suppl 2):S30-S35.
307. Pack A.M., Morrell M.J., Marcus R., Holloway L., Flaster E., Done S., Randall A., Seale C., Shane E. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005, 57:252-257.
308. Verrotti A., Greco R., Latini G., Morgese G., Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002, 43:1488-1492.
309. Verrotti A., Greco R., Morgese G., Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000, 47:385-388.
310. Garnero P., Sornay-Rendu E., Claustrat B., Delmas P.D. Biochemical markers of bone turnover, endogenous hormones,and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000, 15:1526-1536.
311. Lidgren L., Walloe A. Incidence of fracture in epileptics. Acta Orthop Scand 1977, 48:356-361.
312. Jaglal S.B., Kreiger N., Darlington G.A. Lifetime occupational physical activity and risk of hip fracture in women. Ann Epidemiol 1995, 5:321-324.
313. Espallargues M., Sampietro-Colom L., Estrada M.D., Sola M., del Rio L., Setoain J., Granados A. Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: A systematic review of the literature. Osteoporos Int 2001, 12:811-822.
314. Vestergaard P. Epilepsy, osteoporosis and fracture risk-A meta-analysis. Acta Neurol Scand 2005, 112:277-286.
315. Souverein P.C., Webb D.J., Petri H., Weil J., Van Staa T.P., Egberts T. Incidence of fractures among epilepsy patients: A population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005, 46:304-310.
316. Ensrud K.E., Walczak T.S., Blackwell T., Ensrud E.R., Bowman P.J., Stone K.L. Antiepileptic drug use increases rates of bone loss in older women: A prospective study. Neurology 2004, 62:2051-2057.
317. Pack A.M., Morrell M.J. Adverse effects of antiepileptic drugs on bone structure: Epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001, 15:633-642.
318. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987, 33:139-144.
319. Pascussi J.M., Robert A., Nguyen M., Walrant-Debray O., Garabedian M., Martin P., Pineau T., Saric J., Navarro F., Maurel P., Vilarem M.J. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005, 115:177-186.
320. Xu Y., Hashizume T., Shuhart M.C., Davis C.L., Nelson W.L., Sakaki T., Kalhorn T.F., Watkins P.B., Schuetz E.G., Thummel K.E. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): Implications for drug-induced osteomalacia. Mol Pharmacol 2006, 69:56-65.
321. Gough H., Goggin T., Bissessar A., Baker M., Crowley M., Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 1986, 59:569-577.
322. Bogliun G., Beghi E., Crespi V., Delodovici L., d'Amico P. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 1986, 74:284-288.
323. Binkley N., Krueger D., Cowgill C.S., Plum L., Lake E., Hansen K.E., DeLuca H.F., Drezner M.K. Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization. J Clin Endocrinol Metab 2004, 89:3152-3157.
324. Isojarvi J.I., Huuskonen U.E., Pakarinen A.J., Vuolteenaho O., Myllyla V.V. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 2001, 42:741-745.
325. Fitzpatrick L.A. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 2004, 5(Suppl 2):S3-S15.
326. Barden H.S., Mazess R.B., Rose P.G., McAweeney W. Bone mineral status measured by direct photon absorptiometry in institutionalized adults receiving long-term anticonvulsant therapy and multivitamin supplementation. Calcif Tissue Int 1980, 31:117-121.
327. Collins N., Maher J., Cole M., Baker M., Callaghan N. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium and alkaline phosphatase in patients at risk of developing antiepileptic drug-induced osteomalacia. Q J Med 1991, 78:113-122.
328. Pignone M.P., Gaynes B.N., Rushton J.L., Burchell C.M., Orleans C.T., Mulrow C.D., Lohr K.N. Screening for depression in adults: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 136:765-776.
329. Forsen L., Meyer H.E., Sogaard A.J., Naess S., Schei B., Edna T.H. Mental distress and risk of hip fracture. Do broken hearts lead to broken bones?. J Epidemiol Community Health 1999, 53:343-347.
330. Whooley M.A., Kip K.E., Cauley J.A., Ensrud K.E., Nevitt M.C., Browner W.S. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:484-490.
331. Sogaard A.J., Joakimsen R.M., Tverdal A., Fonnebo V., Magnus J.H., Berntsen G.K. Long-term mental distress, bone mineral density and non-vertebral fractures. The Tromso Study. Osteoporos Int 2005, 16:887-897.
332. Mussolino M.E. Depression and hip fracture risk: The NHANES I epidemiologic follow-up study. Public Health Rep 2005, 120:71-75.
333. Yazici K.M., Akinci A., Sutcu A., Ozcakar L. Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res 2003, 117:271-275.
334. Kahl K.G., Rudolf S., Stoeckelhuber B.M., Dibbelt L., Gehl H.B., Markhof K., Hohagen F., Schweiger U. Bone mineral density, markers of bone turnover, and cytokines in young women with borderline personality disorder with and without comorbid major depressive disorder. Am J Psychiatry 2005, 162:168-174.
335. Konstantynowicz J., Kadziela-Olech H., Kaczmarski M., Zebaze R.M., Iuliano-Burns S., Piotrowska-Jastrzebska J., Seeman E. Depression in anorexia nervosa: A risk factor for osteoporosis. J Clin Endocrinol Metab 2005, 90:5382-5385.
336. Kavuncu V., Kuloglu M., Kaya A., Sahin S., Atmaca M., Firidin B. Bone metabolism and bone mineral density in premenopausal women with mild depression. Yonsei Med J 2002, 43:101-108.
337. Yazici A.E., Bagis S., Tot S., Sahin G., Yazici K., Erdogan C. Bone mineral density in premenopausal women with major depression. Joint Bone Spine 2005, 72:540-543.
338. Schweiger U., Deuschle M., Korner A., Lammers C.H., Schmider J., Gotthardt U., Holsboer F., Heuser I. Low lumbar bone mineral density in patients with major depression. Am J Psychiatry 1994, 151:1691-1693.
339. Schweiger U., Weber B., Deuschle M., Heuser I. Lumbar bone mineral density in patients with major depression: Evidence of increased bone loss at follow-up. Am J Psychiatry 2000, 157:118-120.
340. Michelson D., Stratakis C., Hill L., Reynolds J., Galliven E., Chrousos G., Gold P. Bone mineral density in women with depression. N Engl J Med 1996, 335:1176-1181.
341. Wong S.Y., Lau E.M., Lynn H., Leung P.C., Woo J., Cummings S.R., Orwoll E. Depression and bone mineral density: Is there a relationship in elderly Asian men? Results from Mr Os (Hong Kong). Osteoporos Int 2005, 16:610-615.
342. Coelho R., Silva C., Maia A., Prata J., Barros H. Bone mineral density and depression: A community study in women. J Psychosom Res 1999, 46:29-35.
343. Robbins J., Hirsch C., Whitmer R., Cauley J., Harris T. The association of bone mineral density and depression in an older population. J Am Geriatr Soc 2001, 49:732-736.
344. Milliken L.A., Wilhelmy J., Martin C.J., Finkenthal N., Cussler E., Metcalfe L., Guido T.A., Going S.B., Lohman T.G. Depressive symptoms and changes in body weight exert independent and site-specific effects on bone in postmenopausal women exercising for 1 year. J Gerontol A Biol Sci Med Sci 2006, 61:488-494.
345. Reginster J.Y., Deroisy R., Paul I., Hansenne M., Ansseau M. Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 1999, 33:133-137.
346. Whooley M.A., Cauley J.A., Zmuda J.M., Haney E.M., Glynn N.W. Depressive symptoms and bone mineral density in older men. J Geriatr Psychiatry Neurol 2004, 17:88-92.
347. Cizza G., Ravn P., Chrousos G.P., Gold P.W. Depression: A major unrecognized risk factor for osteoporosis?. Trends Endocrinol Metab 2001, 12:198-203.
348. Thapa P.B., Gideon P., Fought R.L., Ray W.A. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am J Epidemiol 1995, 142:202-211.
349. Leipzig R.M., Cumming R.G., Tinetti M.E. Drugs and falls in older people: A systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999, 47:40-50.
350. Granek E., Baker S.P., Abbey H., Robinson E., Myers A.H., Samkoff J.S.,
351. Liu B., Anderson G., Mittmann N., To T., Axcell T., Shear N. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998, 351:1303-1307.
352. Ensrud K.E., Blackwell T., Mangione C.M., Bowman P.J., Bauer D.C., Schwartz A., Hanlon J.T., Nevitt M.C., Whooley M.A. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163:949-957.
353. Schneeweiss S., Wang P.S. Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J Clin Psychopharmacol 2004, 24:632-638.
354. Pacher P., Ungvari Z. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 2001, 57:469-471.
355. Weintrob N., Cohen D., Klipper-Aurbach Y., Zadik Z., Dickerman Z. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002, 156:696-701.
356. Warden S.J., Robling A.G., Sanders M.S., Bliziotes M.M., Turner C.H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146:685-693.